The maladaptive drug memory developed between the drug-rewarding effect and environmental cues contributes to difficulty in preventing drug relapse. Established reward memories can be disrupted by pharmacologic interventions following their reactivation. Rapamycin, an inhibitor of mammalian target of rapamycin (mTOR) kinase, has been proved to be involved in various memory consolidation. However, it is less well characterized in drug memory reconsolidation. Using a conditioned place preference (CPP) procedure, we examined the effects of systemically administered rapamycin on reconsolidation of drug memory in rats. We found that systemically administered rapamycin (0.1 or 10 mg/kg, i.p.) after re-exposure to drug-paired environment, dose dependently decreased the expression of CPP 1 d later, and the effect lasted for up to 14 d and could not be reversed by a priming injection of morphine. The effect of rapamycin on morphine-associated memory was specific to drug-paired context, and rapamycin had no effect on subsequent CPP expression when rats were exposed to saline-paired context or homecage. These results indicated that systemic administration of rapamycin after memory reactivation can persistently inhibit the drug seeking behaviour via disruption of morphine memory reconsolidation in rats. Additionally, the effect of rapamycin on memory reconsolidation was reproduced in cocaine CPP and alcohol CPP. Furthermore, rapamycin did not induce conditioned place aversion and had no effect on locomotor activity and anxiety behaviour. These findings suggest that rapamycin could erase the acquired drug CPP in rats, and that mTOR activity plays an important role in drug reconsolidation and is required for drug relapse.
Introduction
Drug addiction is a chronic, relapsing brain disorder (O'Brien and McLellan, 1996; Leshner, 1997) . Relapse to drug seeking after prolonged abstinence is a major clinical problem (Grimm et al., 2001; Lu et al., 2005; Li et al., 2008a; Millan et al., 2013) . Over the past decade, clinical and laboratory observations have converged on the molecular and cellular adaptations of addiction which share the same neurotrophic factors, certain intracellular signaling cascades, with learning and memory (Nestler, 2001b (Nestler, , 2002 Hyman et al., 2006; Li et al., 2011) . Studies have demonstrated that memory consolidation requires protein synthesis to transform newly learned information into stable memories (Davis and Squire, 1984; McGaugh, 2000) . When this stabilized memory is recalled or reactivated, it undergoes additional consolidation, known as reconsolidation, which requires de novo protein synthesis mediated by receptors, signal transduction pathways and proteins. This reactivated memory is, however, labile and becomes sensitive to disruptors, including receptor antagonist, pharmacological techniques and proteinsynthesis inhibitors (Sara, 2000; Nestler, 2001b Nestler, , 2002 Hyman et al., 2006; Tronson et al., 2006; Tronson and Taylor, 2007) . Similarly, the reactivation of a consolidated drug reward memory also returns to a labile state, vulnerable to amnestic treatment, and impairs drug seeking (Lee et al., 2005 (Lee et al., , 2009 Miller and Marshall, 2005; Hellemans et al., 2006; Mierzejewski et al., 2008; Wang et al., 2008) . Protein synthesis inhibitors (anisomycin or cyclohexamide) administrated immediately after reactivation, can disrupt drug reward memory, leading to the absence of addictive behaviour (Milekic et al., 2006; Valjent et al., 2006; Robinson and Franklin, 2007; Fan et al., 2010) . A better understanding of the molecular and cellular mechanisms of reconsolidation of drug-related memory may lead to novel interventions to prevent drug relapse in humans.
The mammalian target of rapamycin (mTOR) kinase regulates a subset of protein synthesis in neurons through phosphorylation of several intracellular targets, including p70 S6 kinase (p70S6K) and eukaryotic initiation factor 4E-binding proteins (4EBPs) which are involved in the initiation of protein translation (Raught et al., 2001; Hay and Sonenberg, 2004) . The mTOR pathway plays an important role in neuroplasticity in the acquisition, consolidation and reconsolidation of multiple memories, including recognition memory, spatial memory and fear memory (Tang et al., 2002; Parsons et al., 2006; Bekinschtein et al., 2007) . Several studies have reported that rapamycin can inhibit drug-seeking in animals and drug-craving in humans after withdrawal. On the other hand, memory retrieval is usually completely impaired by protein synthesis inhibitors (Shi et al., 2009; Neasta et al., 2010; Wang et al., 2010; Bailey et al., 2012; Dayas et al., 2012) . Rapamycin, an inhibitor of mTOR, frequently used in organ transplantation to prevent rejection via the inhibition of protein synthesis, can successfully enter the brain in rats and humans. mTOR activity is required for protein synthesis-dependent long-term synaptic plasticity and memory storage (Casadio et al., 1999; Stoica et al., 2011) , and systemic or local inhibition of mTOR activity with rapamycin impairs the reconsolidation of contextual fear memory, cued fear memory or recognition memory (Blundell et al., 2008; Glover et al., 2010; Gafford et al., 2011; Jobim et al., 2012) . However, little is known about its effects on reconsolidation of drug-related memories in the morphine-, cocaine-and alcohol-conditioned place preference (CPP) animal model.
The main neurobiology mechanism leading to relapse is the neuroplasticity involved in gene expression and protein synthesis in the mesolimbic dopamine system (Nestler, 2001a (Nestler, , 2002 Kelley, 2004) . Some studies have demonstrated that the mTOR signaling pathway is involved in the neuroadaptations that occur with longterm drug exposure. Pharmacologic inhibition of the mTOR pathway attenuates the induction or expression of drug CPP and behavioural sensitization (Cui et al., 2010; Bailey et al., 2012; Wu et al., 2011) , and reduces cue-induced cocaine seeking behaviour (Wang et al., 2010) . Therefore, in this study, using a typical protocol for drug reward memory, CPP, we examined the effect of rapamycin on reconsolidation of drug reward memory.
Materials and methods

Subjects
Male Sprague-Dawley rats (weighing 220-250 g) were housed in groups of four in a temperature (23 ± 2°C) and humidity (50 ± 5%) controlled animal facility. The rats were randomized into several groups with ad libitum access to food and water. A total of 187 rats (including 11 rats discarded in baseline preference test) were used in the experiments described below. Rats weighed 300-320 g when the experiments began. The experimental procedures were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and were approved by the local Animal Care and Use Committee.
Drugs
Morphine sulfate (Qinghai Pharmaceutical Ltd, China), cocaine HCl (Qinghai Pharmaceutical Ltd), and alcohol (Sigma-Aldrich, USA) were dissolved in 0.9% physiological saline and injected at a volume of 1 ml/kg, while the pH of the drug solution was adjusted to 7.3. For the systemic administration, rapamycin was dissolved in vehicle which contained 4% ethanol, 4% PEG400 and 2% Tween 80. All drugs were freshly prepared before the experiments. Doses of drugs were based on previous reports (Zhu et al., 2007; Li et al., 2008a, b) .
Conditioned place preference (CPP)
In this study, all CPP training procedures were based on our previous studies (Li et al., 2008a, b) and performed using an unbiased, counterbalanced protocol. The CPP apparatus consisted of five identical three-chamber polyvinyl chloride (PVC) boxes. Two large side chambers (27.9 cm long, 21.0 cm wide, 20.9 cm high) were separated by a smaller one (12.1 cm long, 21.0 cm wide, 20.9 cm high with a smooth PVC floor). The two larger chambers differed in their floor texture (bar or grid, respectively), and provided distinct visual contexts that were paired with drug or saline injection. The three distinct chambers were separated by manual guillotine doors.
To determine the baseline preference, rats were initially placed in the middle chamber with the doors removed for 15 min (preconditioning test). A computer measured the time spent in the designated saline-or morphine-paired chambers during the 15 min session through interruption of infrared beams by animals. Most rats spent approximately one third of the time in each chamber (data not shown). Approximately 5% of the total rats were discarded because of a strong unconditioned preference (540 s). Conditioning was performed using an unbiased, balanced protocol.
On the subsequent conditioning days, each rat was trained for eight consecutive days with alternate injections of drug (morphine 10 mg/kg, s.c., cocaine 10 mg/kg, i.p., and alcohol 0.5 mg/kg, s.c.) and saline (morphine and alcohol control, 1 ml/kg, s.c., cocaine control, 1 ml/kg, i.p.). After each injection, rats were confined to the corresponding conditioning chambers for 45 min before returning to their home cages. The day after conditioning, rats were tested for the expression of drug (postconditioning test) CPP under conditions identical to those described in the preconditioning test. The CPP score was defined as the time spent in the morphinepaired chamber minus that spent in the morphineunpaired (saline-paired) chamber (Harris et al., 2005) .
Drug-memory reactivation
Rats were confined to the drug-paired (including morphine, cocaine and alcohol) chamber for 10 min to selectively reactivate drug reward memory (Milekic et al., 2006) and then given the different experimental treatments (see Experimental design).
Retesting and priming of morphine CPP
One day (post-treatment 1) or 2 wk (post-treatment 14) after memory reactivation, rats were retested for morphine CPP. If rats did not demonstrate drug CPP 2 wk after reactivation, they were administered a priming drug dose (morphine 3 mg/kg, s.c., cocaine 5.0 mg/kg and alcohol 0.25 mg/kg, i.p) and immediately tested again (priming test).
Locomotor activity
The behavioural locomotor activity test was based on our and others' previous studies (Boudreau and Wolf, 2005; Li et al., 2008b) . Briefly, rats were habituated to the behavioural testing procedure by being placed in photocell cages for at least 1 h. They then received an injection of drug/vehicle and were immediately placed in the chambers. Ambulation behaviour was measured for 60 min. After each trial, the chamber was carefully cleaned.
Elevated plus maze test
The test was performed between 08:00 hours and 11:00 hours the day after the open field test. The procedure was based on that used in a previous study (Sobrian et al., 2003) . Briefly, the test consists of two opposing open arms (50 × 10 cm) perpendicular to two enclosed arms (50 × 10 × 50 cm) that extend from a central platform (10 × 10 cm), elevated 65 cm above the floor. The rats were placed individually on the central platform facing a closed arm and allowed to explore the maze for 5 min. Their behaviour was monitored using a video camera and analysed with a computerized tracking system. The percentage time spent and the number (frequency) of entries into the centre, open and closed arms were recorded. The entire apparatus was cleaned with 1% acetic acid solution and dried properly between each test.
Experimental design
Experiment 1: effect of rapamycin on reconsolidation of morphine reward memory
To determine the effect of rapamycin on morphine reward memory reconsolidation, rats were trained for morphine (10 mg/kg, s.c.) CPP and randomly divided into two sets, each set included three groups which were matched for CPP score. Twenty-four hours after the post-conditioning, one set of rats were injected with rapamycin (0, 1 or 10 mg/kg, i.p.) immediately after re-exposure to the previously morphine-paired chambers for 10 min, the other set of rats were injected with the same dose of rapamycin (0, 1 or 10 mg/kg, i.p.) but after re-exposure to the previously saline-paired chambers for 10 min. Based on the above experiment results, we further determined whether the inhibitory effect of rapamycin on memory was retrieval-dependent. Three additional groups of rats were given the same treatments, except that they were not re-exposed to the previously morphine-or saline-paired chambers. Rats were retested for morphine CPP 1 d or 2 wk after memory reactivation. If CPP expression was impaired after reactivation, they were administered an injection of priming morphine (3 mg/kg, s.c.,) and immediately tested for CPP again.
Experiment 2: effect of rapamycin on reconsolidation of cocaine and alcohol reward memory
To determine the general effect of rapamycin on drug rewarding memory reconsolidation, we used another three groups of rats training CPP with cocaine (10 mg/kg, i.p.) or alcohol (0.5 mg/kg, i.p.) and tested for CPP as described above. One day after post-conditioning, rats were systemically administered rapamycin (0, 10 mg/kg, i.p.) immediately after re-exposure to the previously cocaine-or alcohol-paired chamber for 10 min. Also, to determine whether the effect of rapamycin on cocaine/ alcohol reward memory was retrieval dependent, four additional groups of rats were given the same treatments, except that they were not re-exposed to the previously cocaine-or alcohol-paired chambers. Then, the rats were measured for the expression of cocaine/alcohol CPP after 1 d or 14 d. On day 15, all rats from all groups not showing CPP were given cocaine and alcohol priming injections (5.0 mg/kg cocaine and 0.25 mg/kg alcohol, i.p.) and immediately tested for CPP score again.
Experiment 3: effect of rapamycin on aversive, locomotor, and anxiety behaviours To exclude the possibility that post-reactivation rapamycin administration produced aversive associative memory between the drug-paired context and the rapamycin injection, which could counteract drug reward memory, another two groups of rats were trained and tested for saline CPP as described above. The day following post-conditioning the rats were systemically administered rapamycin (10 mg/kg, i.p.) immediately after re-exposure to one of the two side chambers (side A and side B). Twenty-four hours later the rats were retested for CPP expression.
We then examined the effect of rapamycin on locomotor activity and anxiety behaviour in rats to ensure selective action on reward memory. Locomotor behaviour and the elevated plus maze test were performed as described above. For locomotor activity, rats were placed in the chambers and their ambulation behaviour was measured for 60 min immediately after receiving rapamycin (0, 10 mg/kg, i.p.) injections. For the elevated plus maze test, however, video tracking software recorded time spent in the open and closed arms and the number of open and closed entries for 5 min.
Statistical analysis
Data were expressed as mean ± S.E.M. A three-way ANOVA was performed on the data with between-factors being dose (0, 1 or 10) and exposure (exposure vs. no-exposure) and the within-factor being test condition (pre, post-conditioning and post-treatment). To test the long-term effects of rapamycin on morphine-, cocaineand alcohol-rewarding memory, one-way repeatedmeasures ANOVA was used to analyse the differences in CPP scores among the test conditions. For locomotor activity, one-way repeated-measures ANOVA was used to analyse the differences in crossings. And one-way ANOVA was used in the elevated plus maze. All post-hoc comparisons were made using Tukey's test. Results with p < 0.05 were accepted as being statistically significant.
Results
Rapamycin disrupts reconsolidation of morphine reward memory
In experiment 1, a three-way ANOVA conducted on CPP score using exposure (exposure to drug-paired, unpaired context or no exposure) and rapamycin (0, 1 or 10 mg/kg) as the between-subjects factors and test condition (preconditioning, post-conditioning and post-treatment 1 or 14) as the within-subjects factor, revealed that there was a significant interaction between exposure × rapamycin × test condition(F 1,287 = 18.19; p < 0.01) and exposure × rapamycin(F 1,287 = 26.23; p < 0.01). Post-hoc analysis showed that after morphine CPP training, all groups acquired CPP (p < 0.001) and there were no differences in CPP scores between any two groups during post-conditioning. Compared with the post-conditioning test, the CPP score was significantly decreased only in the group of rats administrated a dose of 10 mg/kg but not 1 mg/kg rapamycin after re-exposure to the previously morphinepaired chamber (p < 0.01) on the post-treatment day 1 or 14, as shown in (Fig. 1a, b) . Thus, the inhibitory effect of rapamycin on reconsolidation of morphine reward memory was dependent on re-exposure to drug-paired context and memory reactivation in a dose-dependent way (Fig. 1b-d) . And this absence of CPP was not reinstated by a morphine priming injection (one-way repeated measures ANOVA showed F 1,168 = 0.55; p > 0.05, compared to post-treatment condition) (Fig. 1e) .
Effect of rapamycin on reconsolidation of cocaine and alcohol reward memory
In experiment 2, to determine the general effect of rapamycin on reconsolidation of cocaine or alcohol reward memory, a three-way ANOVA showed a significant interaction of exposure (exposure or no exposure) × rapamycin (0, 1 or 10 mg/kg) × test condition (preconditioning, postconditioning, post-treatment 1 or post-treatment 14) (for cocaine CPP: F 1,168 = 6.14; p < 0.05, for alcohol CPP: F 1,168 = 9.12; p < 0.05), rapamycin × test condition (for cocaine CPP: F 6,168 = 5.99; p < 0. 01, for alcohol CPP: F 6,168 = 5.47; p < 0.01), and exposure × test condition (for cocaine CPP: F 2,168 = 7.15; p < 0.01, for alcohol CPP: F 2,168 = 8.29; p < 0.01). Post-hoc analysis showed that after cocaine or alcohol CPP training, all rats acquired CPP (p < 0.01), and there were no differences in CPP scores between any two groups during post-conditioning. However, CPP was inhibited after post-treatment (post-treatment 1) in groups of rats receiving rapamycin after re-exposure (p < 0.01 for10 mg/kg) (Fig. 2b, c, left) ; CPP was not altered in groups of rats administered rapamycin but not reactivation (p > 0.01) (Fig. 2b, c, right) . Fourteen days after reactivation (post-treatment 14), CPP did not recover in rats administered rapamycin with memory reactivation. The effect of rapamycin was not altered by repeated CPP test because there were no significant differences in CPP scores between post-treatment 14 and post-conditioning or post-treatment 1 (p < 0.05) in all vehicle treatment or non-exposure groups. To examine whether this disruption was persistent due to rapamycin, rats showing no CPP were administered a priming injection, and a oneway ANOVA showed that there were no significant differences in CPP scores between the priming test and post-treatment 1 or 14, indicating that a drug priming injection did not reinstate cocaine or alcohol CPP (Fig. 2b, c, left) . Together, these results indicate that the inhibitory effect of rapamycin on memory reconsolidation is also effective for other drugs including cocaine and alcohol.
Effect of rapamycin on aversive, locomotor and anxiety behaviours
To exclude whether rapamycin would produce an aversive effect, rats were trained for CPP in saline. After 8 d of conditioning, rats did not show any preference or aversion toward either side chamber. Then, rats were exposed to rapamycin injection after re-exposure to one of the side chambers. A two-way ANOVA showed that a single rapamycin injection did not produce conditioned place aversion with re-exposure to both sides of chamber (F 2,168 = 0.03; p > 0.05) (Fig. 3a) .
To detect the effect of acute administration of 10 mg/kg rapamycin (a dose that impairs morphine rewarding memory reconsolidation) on locomotor activity or anxiety-like behaviour in rats as measured by the locomotor procedure and the elevated plus maze. A two-way repeated measures ANOVA showed that rapamycin injection did not alter rat locomotor activity (Fig. 3b , p> 0.05), the time spent in the open arm (Fig. 3c, p=0 .63) or closed arm (Fig. 3c , p= 0.21), and number of open arm entries (data not shown, p= 0.68) of the elevated plus maze. These control data further support a selective effect of rapamycin on morphine rewarding memory reconsolidation.
Discussion
In the present study, we investigated the effect of rapamycin on reconsolidation of morphine, cocaine and alcohol related memories. We found that systemic rapamycin injection disrupted morphine reward memories after a retrieval session, and the effect was long-lasting. Additionally, rapamycin did not have any effect when no exposure session or exposure to drug unpaired context was conducted. Thus, the memory impairment was dependent on memory retrieval. Importantly, systemic administration of rapamycin after retrieval also impaired memory reconsolidation of cocaine and alcohol, which indicated that these inhibitory effects of rapamycin on reconsolidation were general for other drug memory, including cocaine and alcohol. Lastly, we excluded the possibility that the effect of post-reactivation rapamycin on CPP score may be attributable to the aversive effect of rapamycin. Using a CPP model, we determined that rapamycin has no aversive effect in this procedure, and we found the effective dose of rapamycin did not alter activity and anxiety-like behaviours.
Relapse is a major clinical problem in addiction. Environmental cues associated with drug use and effects produced maladaptive drug-related memory, which was a major cause of drug relapse (Wikler, 1973; Childress et al., 1986) . Clinically, the difficulty in preventing relapse is due to the drug-associated environmental cues eliciting craving to induce the drug-seeking behaviours (Stewart, 1984; Pert et al., 1990; Robinson and Berridge, 1993) . The phenomenon of memory reactivation followed by memory re-stabilization is known as reconsolidation (Sara, 2000) . The ability to disrupt the expression of memory was referred to as 'cue-dependent amnesia' (Przybyslawski and Sara, 1997; Nader et al., 2000) . Disruption of the reconsolidation of drug-related memories has been suggested as a potential strategy to prevent relapse. A growing body of studies has determined the neuronal events, including receptors, signal transduction pathways and proteins, that mediate drug reward memory reconsolidation (Lee et al., 2005 (Lee et al., , 2009 Miller and Marshall, 2005; Hellemans et al., 2006; Tronson et al., 2006; Tronson and Taylor, 2007; Mierzejewski et al., 2008; Wang et al., 2008) . All these neuronal processes could be targeted to disrupt memories underlying addiction behaviour. In the present study, we found systemic rapamycin administration after memory reactivation produced a long-lasting effect on drug-related memory. It is noted that rapamycin has been used in heroin addicts, and Shi et al. (2009) found that a single dose of rapamycin significantly reduced the craving. Thus, inhibition of the mTOR signaling pathway after memory reactivation maybe an effective way to prevent drug seeking and relapse. The mTOR activity is required for protein synthesisdependent long-term synaptic plasticity and memory storage (Casadio et al., 1999; Stoica et al., 2011) and is involved in fear memory reconsolidation (Blundell et al., 2008) . For example, Blundell et al. (2008) and Glover et al. (2010) found that systemically administered rapamycin, in conjunction with therapeutic traumatic memory reactivation, can decrease the emotional strength of an established traumatic memory. Gafford et al. (2011) demonstrated that the translational control via mTOR pathway in dorsal hippocampus is important for consolidation as well as the stability of fear memory after retrieval. Additionally, Jobim et al. (2012) reported that mTOR inhibition by rapamycin in the basolateral amygdale or dorsal hippocampus impairs both formation and reconsolidation of memory for inhibitory avoidance and novel object recognition in rats. Recently, Barak et al. (2013) showed that reconsolidation of alcohol-related memories triggered by the sensory properties of alcohol itself, which activates the mTOR complex 1 (mTORC1) in select amygdalar and cortical regions in rats. Systemic or central amygdalar inhibition of mTORC1 during reconsolidation disrupts alcohol-associated memories, leading to a long-lasting suppression of relapse in alcohol self-administration. Consistent with these studies, we found systemic rapamycin impaired reconsolidation of morphine, cocaine and alcohol CPP memories. The previous studies and ours, taken together, suggest that mTOR activity may play a general role in the process of memory consolidation and reconsolidation.
The mTOR signaling pathway has been implicated in regulating stimulant-induced sensitization and drug abuse disorder in rodents, as well as drug craving in abstinent heroin addicts (Shi et al., 2009; Wu et al., 2011; Bailey et al., 2012; Yu et al., 2013) . Bailey et al. (2012) and Cui et al. (2010) found that rapamycin attenuated the expression of the cocaine CPP and formation of morphine CPP. Also, Bailey et al. (2012) and Wu et al. (2011) found that inhibition of mTOR by rapamycin blocked the induction as well as the expression of cocaine-induced locomotor sensitization in rats. Wang et al. (2009) that administration of alcohol and excessive voluntary consumption of alcohol induced the activation of the mTOR signaling pathway in the nucleus accumbens of rodents, and rapamycin could decrease expression of alcohol-induced locomotor sensitization and place preference, as well as excessive alcohol intake and seeking in preclinical rodent models of alcohol abuse. In heroin addicts, a study also indicated that a single dose of rapamycin significantly reduced the craving, but not anxiety induced by drug-related cues (Shi et al., 2009) . Our study extends these findings, and suggests that mTOR signaling pathway play a critical role in re-stabilization of drug-associated behaviour. However, previous studies have shown that systemic administration of rapamycin impairs the expression of CPP, although some may argue that rapamycin administration immediately after re-exposure only inhibits the expression of CPP, rather than disrupting the reconsolidation. It is noted that in experiment 1, we used three other groups of rats to examine the effect of rapamycin administrated without re-exposure to context on the CPP score, and found that the CPP expression was not affected. Thus, the impaired effect of rapamycin after retrieval on drug CPP was not due to long-lasting inhibitory effect of rapamycin.
In conclusion, our present study is the first to demonstrate that systemic inhibition of mTOR with rapamycin following a drug memory reactivation blocked its reconsolidation to prevent drug craving and reinstatement in a lasting way. These findings extended previous reports and indicated that mTOR activity plays an important role in drug reconsolidation and is required for the process of drug relapse. Rapamycin is a Food and Drug Administration-approved drug used for the prevention of host rejection of organ transplants (Hartford and Ratain, 2007) . Therefore, our data in this study put forward the possibility that rapamycin targeting the mTOR signaling cascade, via disrupting reward memory reconsolidation, is an innovative and valuable treatment strategy for drug abuse.
